| Date | Title | Description |
| 17.07.2026 | EQT AB (publ) Half-year Report 2026 | EQT AB (publ) Half-year Report 2026
Fri, Jul 17, 2026 07:00 CET Report this content
Strong progress and performance in H1
“In a volatile environment we were able to unlock attractive primary deals and make strong progress on our value creat... |
| 07.05.2026 | Healthtech: 10 companies that raised the most in 2025 | In 2025, Europe’s healthtech ecosystem showed strong funding momentum, with capital concentrated in large rounds across biotech, medtech, digital health, and AI-enabled healthcare. The biggest deals came from companies such as Oura Health, ... |
| 07.04.2026 | Gilead приобретает немецкого производителя противораковых препаратов Tubulis за $5 млрд | Во вторник американская фармкомпания Gilead объявила о планах приобретения частной немецкой компании Tubulis GmbH за сумму до $5 млрд. Сделка направлена на расширение портфеля компании за счет перспективного класса экспериментальных противо... |
| 07.04.2026 | Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead’s oncology pipeline. | Andera Partners today announced that Gilead Sciences, Inc. (Nasdaq: GILD) has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-dru... |
| 12.02.2026 | From industrial depth to strategic growth: the German tech ecosystem | In 2025, European tech companies raised approximately €72 billion in total funding. Germany secured €11.5 billion across 539 deals, accounting for around 16 per cent of the total capital invested and ranking second among European countries ... |
| 23.01.2026 | ErVimmune Unlocks €17M for Groundbreaking Cancer Vaccine Trials | ErVimmune, a Lyon-based biotech, secured €17 million in Series A funding. This pivotal investment propels its innovative off-the-shelf cancer vaccine, ErVac01, into human clinical trials. The company pioneers therapeutic vaccines targeting ... |
| 21.01.2026 | French BioTech company ErVimmune raises €17 million to tackle hard-to-treat cancers | ErVimmune, a BioTech company out of Lyon developing cancer vaccines and cell therapies that target ‘cold tumors’ – cancers that do not respond to current immunotherapies – today announces the first closing of its €17 million ($19.8 million)... |
| 11.01.2026 | Engitix Secures $25M to Advance Cancer, Fibrosis Therapies | British biotech innovator Engitix recently secured a significant $25 million Series A extension. Netherton Investments, acting for Mike Platt, drove this key financing. The capital fuels Engitix’s advanced extracellular matrix (ECM)-targete... |
| 08.01.2026 | London’s Engitix secures €21 million extension to advance ECM-targeted cancer and fibrosis therapies | Engitix, a British BioTech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a €21 million ($25 million) Series A extension financing.
The financing ... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 10.11.2025 | October 2025's top 10 European tech deals you need to know about | October 2025 closed with €8.3 billion raised across 342 deals, slightly softer than September, down 1.2 per cent in value and 6.8 per cent in deal count.
Year over year, activity was markedly stronger: investment volume more than doubled, a... |
| 03.11.2025 | Tubulis: Second Tranche Of €344 Million Series C Closed To Advance ADC Pipeline | Tubulis announced the second and final closing of its Series C financing round, bringing the total raised to €344 million ($401 million). The round included new investors Fidelity Management & Research Company, Janus Henderson Investors... |
| 30.10.2025 | Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M) | • New investors Fidelity Management & Research Company, Janus Henderson Investors and Blackstone Multi-Asset Investing join Series C syndicate led by Venrock Healthcare... |
| 30.10.2025 | Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M) |
MUNICH, GERMANY, October 30, 2025 – Tubulis today announced a second and final closing of its Series C round totaling €344M (US $401M). The second closing brought in additional new investors Fidelity Management & Research Company, Janu... |
| 17.10.2025 | Oura raises over $900M, startups embracing "AI roll-up" strategies, and H1's biggest European gaming deals | This week, we tracked more than 85 tech funding deals worth over €2.2 billion, and over 10 exits, M&A transactions, rumours, and related news stories across Europe.
In addition to this week's top financials, we've also indexed the most ... |
| 16.10.2025 | With its notable €105 million raise, French BioTech startup Adcytherix looks to tackle cancer with novel ADC | Marseille-based Adcytherix, a biopharmaceutical company developing novel and proprietary antibody drug conjugates (ADC), has raised €105 million in a Series A financing round to advance its lead candidate and treat high unmet need diseases
... |
| 16.10.2025 | German biotech Tubulis secures record-breaking €308M Series C | Tubulis, a pioneer in the development of uniquely matched antibody-drug conjugates (ADCs), this week announced the successful closing of a €308 million Series C financing round.
This landmark round marks the largest Series C raised by a Eur... |
| 15.10.2025 | Tubulis Raises €308M In Series C Funding | Tubulis, a Munich, Germany-based oncology company, closed a €308 million (USD 361m) Series C financing.
The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Asce... |
| 15.10.2025 | Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline | • USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally
• Round led by Venrock Healthcare Capital Partners with participation from other new... |
| 15.10.2025 | Tubulis nets $361M financing as next-gen ADC data drop nears | As Tubulis prepares to unveil the first in-human data on its next-generation antibody drug conjugate (ADC) later this month, the German biotech has secured a massive new financing round to kick its clinical strategy into high gear.
Fierce B... |
| 15.10.2025 | Andera Partners Reinvests in Tubulis’ €308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline | Andera Partners, a leading European private equity player, today announced that it participated in the €308 million (USD 361 million) Series C financing of its portfolio company Tubulis, underscoring Andera’s continued support of the compan... |
| 15.10.2025 | Tubulis: €308 Million Series C Secured To Advance Clinical Development Of Lead ADC Candidate TUB-040 | Tubulis announced the closing of a €308 million ($361 million) Series C financing round aimed at accelerating the clinical development of its lead antibody-drug conjugate (ADC) candidate, TUB-040. The round was led by Venrock Healthcare Cap... |
| 15.10.2025 | Munich-based Tubulis secures €308 million to advance antibody-drug conjugate innovation | - |
| 22.05.2025 | BioArctic and Tubulis: Pioneering New Frontiers in Biopharma | In the ever-evolving landscape of biopharmaceuticals, two companies stand out: BioArctic and Tubulis. Both are making waves with innovative treatments that promise to change the game for patients suffering from neurodegenerative diseases an... |
| 21.05.2025 | Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic | MUNICH, GERMANY, May 20, 2025 – Tubulis today announced that the first program from its strategic license agreement with Bristol Myers Squibb has entered clinical development, triggering a significant milestone in the ongoing collaboration ... |
| 09.07.2024 | Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom | Andera Partners, a leading European private equity player, announced today that it is co-leading a € 63 million ($ 70 million) Series A financing for SciRhom, a biopharmaceutical company pioneering the development of first-in-class therapeu... |
| 21.06.2024 | Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma | The multicenter, first-in-human, dose escalation and optimization Phase I/IIa study aims to investigate the safety, tolerability, pharmacokinetics, and efficacy of TUB-040 as a monotherapy. The trial will be conducted in the US as well as t... |
| 25.03.2024 | Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline | Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. |
| 17.03.2024 | Tubulis Secures €128M Series B2 Funding for Cancer Treatment Advancements | Tubulis, a Munich-based biotech startup, has successfully closed an upsized €128 million Series B2 financing round to accelerate the clinical development of its solid tumor-focused ADC pipeline. The funding, co-led by EQT Life Sciences and ... |
| 14.03.2024 | German biotech Tubulis rides wave of ADC interest to $138M financing round | The antibody-drug conjugate (ADC) craze shows no signs of slowing down any time soon, judging by Tubulis’ latest financing.
The German biotech raked in 128 million euros ($138.8 million) in an upsized series B2 financing, which will be used... |
| 14.03.2024 | m4 Award winner Tubulis on the road to success: 128 million euros in Series B2 funding for the fight against solid tumors | The Munich Biotech-Startup and m4 Award winner Tubulis, located in Planegg/Martinsried closes an upsized EUR 128 million Series B2 to accelerate clinical of solid tumor-focused ADC pipeline.
Tubulis today announced the successful completio... |
| 14.03.2024 | Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline | Andera Partners’ portfolio company Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led by EQT Life Sciences and Nextech Invest Ltd, on be... |
| 14.03.2024 | Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline |
MUNICH, GERMANY, March 14, 2024 – Tubulis, a Fund+ portfolio company, today announced the successful completion of an upsized and oversubscribed EUR 128 million (USD 138.8 million) Series B2 financing. The round was co-led by EQT Life Scie... |
| 14.03.2024 | Tubulis Closes Upsized €128M Series B2 Funding | Tubulis, a Munich, Germany-based oncology company, closed an upsized €128m ($138.8m) Series B2 financing.
The round was co-led by EQT Life Sciences and Nextech Invest Ltd, on behalf of one or more funds managed by it, with participation fro... |
| 04.05.2022 | Tubulis picks up €60M Series B | Munich-based biotech startup Tubulis has raised €60 million in a round led by Andera Partners. The startup discovers and develops new antibody-drug conjugates for therapeutic use.
View details |
| 04.05.2022 | Super rich individuals are private equity’s growing LP base | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
It’s been happening over a decade. Rather than settle on endowments or pension funds, the biggest... |
| 03.05.2022 | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies | May 3, 2022 |
| 03.05.2022 | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies | Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec... |
| 03.05.2022 | Tubulis Closes €60M Series B Financing | Tubulis, a Munich, Germany-based generator of matched protein-drug conjugates, raised 60M in Series B funding.
The round was led by Andera Partners with participation from Evotec, Fund+, Bayern Kapital, BioMedPartners, coparion, High-Tech G... |
| 03.05.2022 | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies |
| 03.05.2022 | Tackling toxicity, Tubulis lands $63M to advance ADC pipeline spearheaded by Adcetris rival | Antibody-drug conjugates (ADCs) have come a long way in recent years. Tubulis wants to advance the modality still further—and has pulled in 60 million euros ($63 million) to bankroll technology to address the persistent toxicity problems fa... |
| 03.05.2022 | Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs | Andera Partners, a leading European private equity player, through its biotech and medtech practice Andera Life Sciences, announced today that it is leading a €60 million (USD $63 million) Series B financing round for Tubulis with participa... |
| 04.11.2020 | EIT Health startups see strong Q3 with €72.7 million funding raised | EIT Health-supported startups have reported a successful quarter three in terms of fundraising, with €72.7 million secured.
The 19 startups hail from 10 European countries and will use the funds to further develop their solutions addressin... |
| 02.11.2020 | These 19 European startups backed by EIT Health have raised a total of €72.7M in Q3’20 | Germany, Munich-based European Institute of Innovation & Technology (EIT), EIT Health has announced that its supported startups have reported a successful Q3 in terms of fundraising, with €72.7M secured.
The 19 startups that hail from 1... |
| 21.07.2020 | Tubulis Raises €10.7M in Series A Funding | Tubulis, a Munich, Germany-based developer of protein-drug conjugates, closed a €10.7m Series A financing round.
The round was co-led by BioMedPartners and High-Tech Gründerfonds (HTGF) with participation from Seventure Partners, coparion, ... |
| 21.07.2020 | EIT Health helps Tubulis secure €10.7M in funding | Tubulis has raised €10.7 million to advance development of a new generation of antibody-drug conjugates with the support of six investors, including two from the EIT Health Investor Network – BioMedPartners and Seventure Partners.
The EIT ... |
| 28.11.2018 | The Innovators Under 35 Europe 2018 | Technology to eliminate the waste of food, solar strips to regenerate burned skin faster and artificial intelligence that analyzes electrocardiograms as well as a real doctor, among the winning projects
The European community will meet on ... |
| - | Tubulis | “Reimagining Antibody Drug Conjugates NEWS May 20 Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic February 06 Tubulis Strengthens Executive Leadership with Appointment... |
| - | Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates | Tubulis today announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company. The ... |
| - | Tubulis | “Reimagining Antibody Drug Conjugates NEWS April 20 Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients March 03 Article on Tubulis’ novel ADC conjugat... |
